Kura Oncology (KURA) EBITDA (2010 - 2026)
Kura Oncology (KURA) reported EBITDA of -$74.7 million for Q1 2026, down 30.62% year-over-year from -$107.7 million in Q1 2025, and up 7.61% quarter-over-quarter from -$80.9 million in Q4 2025.
Kura Oncology (KURA) EBITDA (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has 17 years of EBITDA data on file, last reported at -$74.7 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$74.7 million, down 30.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$295.9 million (down 64.31% YoY), and the FY2025 annual result was -$278.4 million, down 61.91% from the prior year.
- EBITDA advanced to -$74.7 million in Q1 2026 per KURA's latest filing, from -$80.9 million in the prior quarter.
- Over five years, EBITDA peaked at -$19.6 million in Q4 2024 and troughed at -$80.9 million in Q4 2025.
- A 5-year average of -$47.8 million and a median of -$40.5 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2024 and 2025: EBITDA soared 51.71% in 2024, then slumped 313.37% in 2025.
- A 5-year view of EBITDA shows it stood at -$31.7 million in 2022, then fell by 27.71% to -$40.5 million in 2023, then soared by 51.71% to -$19.6 million in 2024, then tumbled by 313.37% to -$80.9 million in 2025, then advanced by 7.61% to -$74.7 million in 2026.
- Business Quant data shows KURA's EBITDA at -$74.7 million in Q1 2026, -$80.9 million in Q4 2025, and -$73.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Kura Oncology | 883.44 Mn | 883.44 Mn | 18.00 Mn | -74.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.74 Mn |
| Dec 31, 2025 | -80.89 Mn |
| Sep 30, 2025 | -73.91 Mn |
| Jun 30, 2025 | -66.39 Mn |
| Mar 31, 2025 | -57.22 Mn |
| Dec 31, 2024 | -19.57 Mn |
| Sep 30, 2024 | -52.83 Mn |
| Jun 30, 2024 | -50.48 Mn |
| Mar 31, 2024 | -49.07 Mn |
| Dec 31, 2023 | -40.52 Mn |
| Sep 30, 2023 | -36.92 Mn |
| Jun 30, 2023 | -36.50 Mn |
| Mar 31, 2023 | -31.93 Mn |
| Dec 31, 2022 | -31.73 Mn |
| Sep 30, 2022 | -37.11 Mn |
| Jun 30, 2022 | -35.94 Mn |
| Mar 31, 2022 | -37.31 Mn |
| Dec 31, 2021 | -34.34 Mn |
| Sep 30, 2021 | -33.17 Mn |
| Jun 30, 2021 | -33.97 Mn |